Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Exploring a Translational Strategy to Evaluate ADC Efficacy & Overcome Payload Specific Resistance Using Topo1 & Tubulin Inhibitor Resistant PDX Models

By | 8 June 2026

Assessing ADC efficacy through in vitro PDXO, MiniPDX, and PDX models
Establishing a unique panel of PDX models to reveal resistance driven by payload mechanism, independent of the target antigen
Validating rational combinations including ADC+IO to overcome immunosuppressive resistance
Informing the design of bispecific or dual payload ADCs, engineered to circumvent resistance pathways